BCL2 and myeloid sarcoma: Interestingly, BCL2, an anti‐apoptotic protein, is expressed by oligodendrocytes and has been found to be increased within demyelinating lesions compared to the peri‐plaque WM, with the highest numbers in remyelinating lesions specifically during relapsing‐remitting disease course,30 thus highlighting oligodendrocyte preservation or loss in MS WMLs.